Optomed Plc
Annual Reports

YEAR 2021

Optomed in brief

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally.

CEO REVIEW

Optomed grew strongly in 2021

“Optomed’s revenue growth was strong in 2021. Growth was especially strong in the first half of the year driven by Western markets recovery from the COVID-19 pandemic. We continued expanding our commercial activities in the United States market as well as strengthening our team, which contributed to the strong growth in the Devices-segment. Also, sales to our OEM customers turned back to growth as expected.”

Seppo Kopsala
CEO

Key figures 2021

Net sales 2020

14,8

EUR, million

Gross margin

71.1

%

Adjusted EBITDA

-2,0

EUR, million

Equity ratio

58.8

%

BUSINESS MODEL

Complete solutions for eye screening

Optomed combines handheld fundus cameras with software and artificial intelligence for image analysis and we sell our products and solutions via several sales channels globally. Our sales channels include our direct sales team, our global distribution network of around 55 partners, our OEM customers as well as our complete eye screening solution sales organization. Optomed has two subsidiaries, in China and in the USA.